drugset / Trial / NCT00226889
Treatment of Early Systemic Sclerosis by Bosentan
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Systemic sclerosis (ssc) is characterised by extensive tissue fibrosis. Using drugs that are capable of inhibiting fibroblast activity may be beneficial if administrered early in the disease course. Thirty adult patients with early SSc will be treated with the endothelin-1 antagonist bosentan for 6 months.Disease progression will be assessed.
Timeline
- Start
- 2005-01
- Primary completion
- 2009-01
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosentan | Other / unclassified | — | Oral |